DXCM (DexCom, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by DXCM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | MARK G FOLETTA | Director | Sell | — | — |
| 2026-07-21 | KEVIN R SAYER | Executive Chair | Sell | — | — |
| 2026-07-16 | Michael Jon Brown | EVP Chief Legal Compliance Off | Sell | — | — |
| 2026-07-07 | KEVIN R SAYER | Executive Chair | Sell | — | — |
| 2026-06-17 | Michael Jon Brown | EVP Chief Legal Compliance Off | Sell | — | — |
| 2026-06-17 | MARK G FOLETTA | Director | Sell | — | — |
| 2026-06-05 | Jon Coleman | EVP, Chief Commercial Officer | Sell | — | — |
| 2026-06-01 | RENEE D GALA | Director | A | — | — |
| 2026-06-01 | Richard Alexander Collins | Director | A | — | — |
| 2026-06-01 | Euan A. Ashley | Director | A | — | — |
| 2026-06-01 | Rimma Driscoll | Director | A | — | — |
| 2026-06-01 | Albert Frederick IV Osterloh | Director | A | — | — |
| 2026-06-01 | Bridgette P Heller | Director | A | — | — |
| 2026-06-01 | MARK G FOLETTA | Director | A | — | — |
| 2026-06-01 | NICHOLAS AUGUSTINOS | Director | A | — | — |
| 2026-06-01 | Kyle Malady | Director | A | — | — |
| 2026-06-01 | STEVEN R ALTMAN | Director | A | — | — |
| 2026-05-27 | Jon Coleman | EVP, Chief Commercial Officer | F | — | — |
| 2026-05-27 | Sadie Stern | EVP Chief People & Culture Off | F | — | — |
| 2026-05-27 | Jereme M Sylvain | EVP, Chief Financal Officer | F | — | — |
| 2026-05-27 | Michael Jon Brown | EVP Chief Legal Compliance Off | F | — | — |
| 2026-05-27 | Jacob Steven Leach | President, CEO, and Director | F | — | — |
| 2026-05-26 | KEVIN R SAYER | Executive Chair | Sell | — | — |
| 2026-05-19 | Michael Jon Brown | EVP, Chief Legal Officer | Sell | — | — |
| 2026-05-14 | Bridgette P Heller | Director | Sell | — | — |
| 2026-05-11 | STEVEN R ALTMAN | Director | G | — | — |
| 2026-05-11 | MARK G FOLETTA | Director | G | — | — |
| 2026-05-11 | Richard Alexander Collins | Director | G | — | — |
| 2026-05-11 | NICHOLAS AUGUSTINOS | Director | G | — | — |
| 2026-04-16 | Michael Jon Brown | EVP, Chief Legal Officer | Sell | — | — |
| 2026-03-18 | Michael Jon Brown | EVP, Chief Legal Officer | Sell | — | — |
| 2026-03-10 | Jon Coleman | EVP, Chief Commercial Officer | A | — | — |
| 2026-03-10 | Jacob Steven Leach | President, CEO, and Director | MIXED | — | — |
| 2026-03-10 | Sadie Stern | EVP, Chief HR Officer | MIXED | — | — |
| 2026-03-10 | Michael Jon Brown | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-03-10 | Jereme M Sylvain | EVP, Chief Financal Officer | MIXED | — | — |
| 2026-03-10 | KEVIN R SAYER | Executive Chair | MIXED | — | — |
| 2026-02-26 | Albert Frederick IV Osterloh | Director | A | — | — |
| 2026-02-17 | Bridgette P Heller | Director | Sell | — | — |
| 2026-02-02 | KEVIN R SAYER | Executive Chair | MIXED | — | — |
| 2026-02-02 | Michael Jon Brown | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-02-02 | Jereme M Sylvain | EVP, Chief Financal Officer | MIXED | — | — |
| 2026-02-02 | Sadie Stern | EVP, Chief HR Officer | MIXED | — | — |
| 2026-02-02 | Jacob Steven Leach | President, CEO, and Director | MIXED | — | — |
| 2025-11-17 | Richard Alexander Collins | Director | Sell | — | — |
| 2025-11-12 | Bridgette P Heller | Director | Sell | — | — |
| 2025-11-10 | Richard Alexander Collins | Director | Sell | — | — |
| 2025-11-10 | Jacob Steven Leach | President & COO | Buy | — | — |
| 2025-10-28 | Euan A. Ashley | Director | A | — | — |
| 2025-09-09 | Kyle Malady | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 8,967,644 | — |
| — | Executive Chairman | 1,972,224 | — |
| — | Director | 1,439,332 | — |
| — | Director | 492,840 | — |
| — | President, CEO, and Director | 467,655 | — |
| — | Director | 380,545 | — |
| — | General Manager, EMEA | 336,136 | — |
| — | Executive Chair | 328,970 | — |
| — | CTO | 303,332 | — |
| — | SVP, CFO | 219,796 | — |
| — | EVP Operations | 217,872 | — |
| — | Director | 211,280 | — |
| — | EVP Global Business Services I | 208,023 | — |
| — | Director | 182,532 | — |
| — | SVP Human Resources | 178,400 | — |
| — | EVP, Chief Financal Officer | 151,841 | — |
| — | EVP Chief People & Culture Off | 130,059 | — |
| — | EVP Managing Director Dexcom V | 124,775 | — |
| — | Chief Operating Officer | 121,212 | — |
| — | EVP Chief Commercial Officer | 114,280 | — |
| — | Chief Financial Officer | 105,020 | — |
| — | EVP Chief Legal Compliance Off | 104,653 | — |
| — | EVP, Chief Commercial Officer | 100,361 | — |
| — | EVP Regulatory Strategy Clinic | 89,515 | — |
| — | VP Marketing | 74,488 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DXCM quote page; the site-wide leaderboard is on the insider transactions hub.